Table 1 Patient baseline characteristics at the initiation of antiviral treatment
Baseline characteristics | Â |
|---|---|
Patient number | 474 |
Age (years) | 58 (50–64) |
Male, n (%) | 230 (48.5) |
Body mass index (kg/m2) | 23.1 (21.0–25.3) |
Alanine aminotransferase (U/L) | 52 (33–81) |
Total cholesterol (mg/dL) | 174 (152–197) |
α-fetoprotein (ng/mL) | 4.1 (2.5–7.2) |
Platelet count (×109/L) | 160 (125–199) |
Hemoglobin A1c (NGSP) (%) | 5.5 (5.3–5.9) |
Fasting plasma glucose (mg/dL) | 93 (87–101) |
Fasting serum insulin (μU/mL) | 8.6 (5.9–13.7) |
HOMA-IR | 1.9 (1.3–3.3) |
HCV RNA level (logIU/mL) | 6.2 (5.7–6.6) |
HCV genotype, n (%) | |
 1a | 4 (0.8) |
 1b | 360 (75.9) |
 2a | 63 (13.3) |
 2b | 47 (9.9) |
Fibrosis stage, n (%) | |
 F0-1 | 241 (50.8) |
 F2 | 104 (21.9) |
 F3 | 76 (16.0) |
 Not determined | 53 (11.2) |
Activity grade, n (%) | |
 A0-1 | 162 (34.2) |
 A2 | 244 (51.5) |
 A3 | 15 (3.2) |
 Not determined | 53 (11.2) |